Company

Novosense AB started in 2004, as a result of research collaboration between Acreo AB,  Tilly Medical AB and Fredrik Sebelius.

A Swedish patent has been granted for Novosenses wireless ECG system and the PCT process is ongoing. The company and has a unique portfolio of production, sensor and radio-technology.

The company is located in Lund, at the Ideon Science Park, which is a dynamic area for technology based companies, in close cooperation with Lund University, the largest university in Scandinavia.

Mission & Vision

The Company is developing and will bring to the market a completely wireless ECG patient monitoring system for use mainly in cardiac care, intensive care and operating theatres.

The company’s vision is to successfully develop and launch the wireless ECG CadioSenseSystem® in hospitals in Europe and the USA and to establish a complete medical device company that is highly profitable. 

The technology meets demands for cost efficiency through low equipment cost and simplified handling.

The Market

The total sales for ECG equipment on Novosense's key markets is estimated to more than 1 billion USD. The market has a growth rate of 7 % per year. 

Novosense is focusing on the CCU market in Europe and North America.